Latest Trustworthy News from Dr. Mercola - delivered straight to your inbox!

GSK and Sanofi COVID-19 Vaccine Produced in Insect Cells With Squalene Adjuvant

coronavirus

Two of the world’s largest vaccine manufacturers are using DNA technology, insect cells and a squalene adjuvant, AS03, as the basis to develop a COVID-19 vaccine together. GlaxoSmithKline (GSK) and Sanofi Pasteur are partners in the enterprise, with clinical trials set to begin in 2020.

The squalene adjuvant is aluminum-based and is designed to induce a higher immune response through an enhanced inflammatory process. While aluminum is currently in other vaccines such as hepatitis, HPV, meningococcal and pneumococcal, evidence that aluminum is neurotoxic has been steadily accumulating in the medical literature.

SOURCE: The Vaccine Reaction May 4, 2020